Patents by Inventor Ingo Focken

Ingo Focken has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10947284
    Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: March 16, 2021
    Assignee: Pieris Pharmaceuticals GmbH
    Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
  • Publication number: 20200262926
    Abstract: Binding proteins comprising a VL region paired with a VH region, and a CH1 region paired with a CL region, wherein the VL region and VH region comprise opposite charged mutations to facilitate pairing, and wherein the CH1 region and CL region comprise mutations to facilitate pairing, are provided. Binding proteins comprising one or more cysteine residues engineered into the VH/VL pair to form one or more disulfide bonds, are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.
    Type: Application
    Filed: December 23, 2019
    Publication date: August 20, 2020
    Inventors: Marta Amaral, Christian Beil, Ingo Focken, Gerhard Hessler, Soraya Hoelper, Jennifer Jung, Christian Lange, Wulf-Dirk Leuschner, Ercole Rao, Garima Tiwari, Sandra Weil
  • Publication number: 20190382455
    Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.
    Type: Application
    Filed: April 24, 2019
    Publication date: December 19, 2019
    Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
  • Patent number: 10316071
    Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: June 11, 2019
    Assignee: SANOFI
    Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
  • Patent number: 9989524
    Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: June 5, 2018
    Assignee: SANOFI
    Inventors: Jochen Kruip, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken
  • Publication number: 20180057567
    Abstract: Provided herein are multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. Also disclosed herein are nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies, as well as methods of isolating the antibodies.
    Type: Application
    Filed: August 25, 2017
    Publication date: March 1, 2018
    Inventors: Ercole Rao, Christian Beil, Christian Lange, Katja Kroll, Wulf-Dirk Leuschner, Ingo Focken, Thomas Langer, Nadja Spindler
  • Patent number: 9844607
    Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: December 19, 2017
    Assignees: SANOFI, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Jochen Kruip, Sanjiv S. Gambhir, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken, Richard Kimura, Arutselvan Natarajan, Ohad Ilovich
  • Publication number: 20170029477
    Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.
    Type: Application
    Filed: July 6, 2016
    Publication date: February 2, 2017
    Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
  • Patent number: 9441040
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: September 13, 2016
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • Publication number: 20150098939
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 9, 2015
    Applicant: SANOFI
    Inventors: Nicolas BAURIN, Francis BLANCHE, Beatrice CAMERON, Carsten CORVEY, Tarik DABDOUBI, Christian ENGEL, Peter FLORIAN, Ingo FOCKEN, Katja KROLL, Jochen KRUIP, Christian LANGE, Thomas LANGER, Martin LORENZ, Vincent MIKOL, Ercole Rao, Peter WONEROW
  • Patent number: 8852593
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion phenotype. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: October 7, 2014
    Assignee: Sanofi
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • Publication number: 20140255305
    Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.
    Type: Application
    Filed: February 5, 2014
    Publication date: September 11, 2014
    Inventors: Jochen Kruip, Sanjiv S. Gambhir, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken, Richard Kimura, Arutselvan Natarajan, Ohad Ilovich
  • Publication number: 20140256916
    Abstract: The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6.
    Type: Application
    Filed: February 5, 2014
    Publication date: September 11, 2014
    Inventors: Jochen Kruip, Susanta K. Sarkar, Mathias Gebauer, Christian Lange, Ingo Focken
  • Patent number: 8470841
    Abstract: Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.
    Type: Grant
    Filed: July 7, 2009
    Date of Patent: June 25, 2013
    Assignee: Sanofi
    Inventors: Gerhard Zoller, Dieter Schmoll, Marco Mueller, Guido Haschke, Ingo Focken
  • Publication number: 20120282637
    Abstract: The present invention relates to a polypeptide or polypeptide complex comprising at least the two amino acid sequences arranged to allow for specific binding to the “receptor for advanced glycation endproducts” (RAGE), one or more nucleic acid(s) coding for the polypeptide or polypeptide complex, a cell producing an antibody against RAGE, a pharmaceutical composition comprising at least one polypeptide or nucleic as defined above, optionally for treating a RAGE-related disease or disorder and a method of diagnosing a RAGE-related disease or disorder.
    Type: Application
    Filed: October 8, 2010
    Publication date: November 8, 2012
    Applicant: SANOFI
    Inventors: Jochen Huber, Francis Blanche, Tarik Dabdoubi, Fabienne Soubrier, Ingo Focken, Jochen Kruip, Kathrin Heermeier, Christian Lange
  • Publication number: 20120244152
    Abstract: The present invention discloses novel antibodies that specifically bind to the human platelet membrane protein Glycoprotein VI (GPVI) and their monovalent fragments or derivatives. The antibodies of the invention are antibodies from hybridoma clone 390 and fragment antibodies thereof able to induce a GPVI depletion pheno-type. These antibodies and Fab fragments are able to block collagen binding and thus preventing platelet activation by collagen. The invention also relates to hybridoma clones and expression plasmids for the production of disclosed antibodies and Fab fragments. The present invention further refers to the uses of monovalent antibody fragments to manufacture research, diagnostic and immunotherapeutic agents for the treatment of thrombosis and other vascular diseases. The invention also concerns a Fab bearing a molecule at the C-terminal extremity, as well as method for prevention of recognition of Fab by antibodies using such modified Fab.
    Type: Application
    Filed: December 17, 2010
    Publication date: September 27, 2012
    Applicant: SANOFI
    Inventors: Nicolas Baurin, Francis Blanche, Beatrice Cameron, Carsten Corvey, Tarik Dabdoubi, Christian Engel, Peter Florian, Ingo Focken, Katja Kroll, Jochen Kruip, Christian Lange, Thomas Langer, Martin Lorenz, Vincent Mikol, Ercole Rao, Peter Wonerow
  • Publication number: 20110183998
    Abstract: Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.
    Type: Application
    Filed: July 7, 2009
    Publication date: July 28, 2011
    Applicant: SANOFI-AVENTIS
    Inventors: Gerhard Zoller, Dieter Schmoll, Marco Mueller, Guido Haschke, Ingo Focken